U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

t(6;14)

MedGen UID:
1778906
•Concept ID:
C5447617
•
Cell or Molecular Dysfunction

Definition

A cytogenetic abnormality that involves a translocation between chromosomes 6 and 14. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVt(6;14)

Professional guidelines

PubMed

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
Ceglédi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H, Mikala G
Pathol Oncol Res 2023;29:1611375. Epub 2023 Nov 10 doi: 10.3389/pore.2023.1611375. PMID: 38025905Free PMC Article
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.
Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK
Blood Cancer J 2020 Aug 11;10(8):82. doi: 10.1038/s41408-020-00348-5. PMID: 32782240Free PMC Article
Application of machine learning algorithms for the differential diagnosis of peroxisomal disorders.
Subhashini P, Jaya Krishna S, Usha Rani G, Sushma Chander N, Maheshwar Reddy G, Naushad SM
J Biochem 2019 Jan 1;165(1):67-73. doi: 10.1093/jb/mvy085. PMID: 30295825

Recent clinical studies

Etiology

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
Ceglédi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H, Mikala G
Pathol Oncol Res 2023;29:1611375. Epub 2023 Nov 10 doi: 10.3389/pore.2023.1611375. PMID: 38025905Free PMC Article

Therapy

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
Ceglédi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H, Mikala G
Pathol Oncol Res 2023;29:1611375. Epub 2023 Nov 10 doi: 10.3389/pore.2023.1611375. PMID: 38025905Free PMC Article

Prognosis

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
Ceglédi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H, Mikala G
Pathol Oncol Res 2023;29:1611375. Epub 2023 Nov 10 doi: 10.3389/pore.2023.1611375. PMID: 38025905Free PMC Article

Clinical prediction guides

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
Ceglédi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H, Mikala G
Pathol Oncol Res 2023;29:1611375. Epub 2023 Nov 10 doi: 10.3389/pore.2023.1611375. PMID: 38025905Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...